Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (234)	6/8/1998 1:33:00 AM
From: Bilow	Respond to of 1722

Hi Anthony Wong; About 'Off-Label" Advertising & PGNS. Pathogenesis (Naz PGNS) got FDA approval for its orphan drug to fight bacterial lung infections in cystic fibrosis (CF) patients earlier this year. They managed to sell about a buck per share their first quarter, and hope to see much larger sales to CF patients for the next decade. That said, they are trying to get the same product (their patent is on an aerosol mist delivery system) into the (much larger) tuberculosis market. Does this FDA 'Off-Label' Advertising ruling mean that PGNS could start selling directly into the TB market? If so, I would think it would really pump their sales up, but I wonder if the ruling applies to drugs that come in under the orphan provision... Any ideas? The stock got hit this past week on an analyst downgrade. I'm thinking about buying some as soon as the price starts to stabilize. -- Carl